Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag.
HIV-associated thrombocytopenia is a disease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag - a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a temporizing measure.
Department of Medicine, Saint Vincent Hospital, Worcester, MA;
Rajakrishnan
R
Vijayakrishnan
Department of Medicine, Saint Vincent Hospital, Worcester, MA;
Sourbha
S
Dani
Department of Medicine, Saint Vincent Hospital, Worcester, MA;
Aparna
A
Ramasubramanian
Department of Medicine, Saint Vincent Hospital, Worcester, MA;
Rekha
R
Nair
Department of Hematology & Oncology, Saint Vincent Hospital, Worcester, MA, USA.
Tony M
TM
Samaha
eltrombopag; hematologic diseases.; hepatitis C; human immunodeficiency virus; thrombocytopenia